Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
RadSABR
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
- NCT03304418 ↗
- Completed
- University of Utah
- Focused
We haven't built an HCP commentary report on RadSABR (radium-223 in hormone-naïve oligometastatic prostate cancer to bone) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RadSABR so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Prostate Cancer Metastatic to Bone
- Interventions
- Radium Ra 223 Dichloride; Radiation
- Arms
- Radium Ra 223 dichloride and radiation, all patients · Experimental
- Enrollment
- 20
- Primary outcomes
- Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months
- Sponsor
- University of Utah with Bayer
- Start
- Feb 27, 2018
- Primary completion
- Sep 30, 2022
- Results posted
- Yes
- Registry record
- NCT03304418 · updated Apr 30, 2025